Trial Profile
An observational study of modified house-dust mite immunotherapy in Spain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy Allergy Therapeutics (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- 31 May 2018 New trial record
- 29 May 2018 Results presented in an Allergy Therapeutics media release.
- 29 May 2018 Data from this trial will be presented at the 37th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2018, according to an Allergy Therapeutics medai release.